Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Cellectar Biosciences, Inc. | v335880_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report: February 21, 2013
(Date of earliest event reported)
NOVELOS THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 333-119366 | 04-3321804 | ||
| (State or other jurisdiction | (Commission | (IRS Employer | ||
| of incorporation) | File Number) | Identification Number) |
One Gateway Center, Suite 504
Newton, MA 02458
(Address of principal executive offices)
(617) 244-1616
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| ITEM 7.01 | REGULATION FD DISCLOSURE |
A copy of the press release issued by us on February 21, 2013 announcing the closing of the previously disclosed $5.5 million registered public offering of units consisting of our common stock and warrants to purchase our common stock is furnished as Exhibit 99.1 and is incorporated by reference.
| ITEM 9.01 | FINANCIAL STATEMENTS AND EXHIBITS |
(d) Exhibits
| Number | Title | |
| 99.1 | Press Release dated February 21, 2013 entitled “Novelos Therapeutics Closes $5.5 Million Public Offering” |
| 2 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Dated: February 21, 2013 | NOVELOS THERAPEUTICS, INC. | |
| By: | /s/ Harry S. Palmin | |
| Name: Harry S. Palmin | ||
| Title: President and Chief Executive Officer | ||
| 3 |
EXHIBIT INDEX
| Number | Title | |
| 99.1 | Press Release dated February 21, 2013 entitled “Novelos Therapeutics Closes $5.5 Million Public Offering” |
| 4 |